Results 111 to 120 of about 13,475,824 (303)

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane   +43 more
wiley   +1 more source

The Dilemma of Treating Delirium: the Conundrum of Drug Management. [PDF]

open access: yesCurr Treat Options Oncol, 2022
Agar MR, Amgarth-Duff I.
europepmc   +1 more source

A Depolarizing Leak in Sodium Bicarbonate Cotransporter NBCe1 Causes Brain Edema

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives SLC4A4 encodes electrogenic sodium bicarbonate cotransporter NBCe1, prominently expressed in kidney and brain. Recessive loss‐of‐function variants in SLC4A4 cause proximal renal tubular acidosis, no brain edema. In the brain, NBCe1 is expressed by astrocytes, where it regulates pH and mediates astrocyte volume changes.
Quinty Bisseling   +16 more
wiley   +1 more source

Persistence with topical glaucoma therapy in Japan from the perspective of product, formulation, and patient characteristics: analysis of medical insurance claim data

open access: yesBMC Ophthalmology
Background Glaucoma is the leading cause of irreversible blindness in Japan and constitutes a serious public health challenge. Due to its asymptomatic onset and slow progression, patient persistence with topical glaucoma therapies remains low ...
Kenji Kabeya   +3 more
doaj   +1 more source

Comparing the Effect of Semi‐Immersive Virtual Reality, Computerized Cognitive Training, and Traditional Rehabilitation on Cognitive Function in Multiple Sclerosis: A Randomized Clinical Trial

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Cognitive impairment is a common non‐motor symptom in Multiple Sclerosis (MS), negatively affecting autonomy and Quality of Life (QoL). Innovative rehabilitation strategies, such as semi‐immersive virtual reality (VR) and computerized cognitive training (CCT), may offer advantages over traditional cognitive rehabilitation (TCR ...
Maria Grazia Maggio   +8 more
wiley   +1 more source

Multiplexed biosensor for point-of-care COVID-19 monitoring: CRISPR-powered unamplified RNA diagnostics and protein-based therapeutic drug management. [PDF]

open access: yesMater Today (Kidlington), 2022
Johnston M   +9 more
europepmc   +2 more sources

Instillation success rates among glaucoma eyedrop products: patient survey in Japan

open access: yesBMC Ophthalmology
Background Glaucoma is the leading cause of blindness in Japan and poses a significant public health challenge. Previous studies have reported low success rates for antiglaucoma eyedrop instillation.
Kenji Kabeya   +3 more
doaj   +1 more source

Acute Kidney Injury After Mechanical Thrombectomy for Stroke in Patients With Pre‐Existing Renal Impairment

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Acute kidney injury (AKI) is a common but often underrecognized complication in ischemic stroke patients undergoing mechanical thrombectomy, particularly among those with pre‐existing renal impairment. This study evaluated the incidence, risk factors, and clinical impact of AKI in this high‐risk population.
Michał Borończyk   +10 more
wiley   +1 more source

Bisphosphonate compliance in Japan from the perspective of product, formulation, and patient characteristics: analysis of medical insurance claim data

open access: yesJournal of Pharmaceutical Health Care and Sciences
Background Bisphosphonates are the mainstay drugs for osteoporosis, but in clinical practice, they are often ineffective due to low compliance. However, there have been few studies examining compliance on a product-by-product basis or in detail in Japan.
Kenji Kabeya   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy